Canaccord lowered the firm’s price target on AngioDynamics to $12 from $13 and keeps a Buy rating on the shares. The firm said they believe they delivered another solid quarter with $67.5M in Q1/25 revenue, but think the stock reaction is driven by missing the consensus revenue estimate and the seasonally high Q1 cash burn.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics reports Q1 adjusted EPS (11c), consensus (15c)
- AngioDynamics sees FY25 adjusted EPS (38c)-(42c), consensus (41c)
- Levi Strauss mulls Dockers strategic alternatives: Morning Buzz
- AngioDynamics Sees Growth Amidst Challenges in Fiscal 2025
- Options Volatility and Implied Earnings Moves Today, October 03, 2024